Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 12:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 35 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Acquired Bleeding Disorder Clear all
Completed Phase 2 Interventional
View directory record Official record
Conditions
Acquired Bleeding Disorder, Spinal Fusion
Interventions
eptacog alfa (activated)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
14
States / cities
Sacramento, California • San Francisco, California • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced May 22, 2026, 12:13 AM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Acquired Bleeding Disorder, Intracerebral Haemorrhage
Interventions
activated recombinant human factor VII, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced May 22, 2026, 12:13 AM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Acquired Factor X Deficiency
Interventions
Coagadex(R)
Biological
Lead sponsor
Kedrion S.p.A.
Industry
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Phoenix, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced May 22, 2026, 12:13 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Acquired Bleeding Disorder, Cardiac Surgery Requiring Cardiopulmonary Bypass
Interventions
catridecacog, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 80 Years
Enrollment
479 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
7
States / cities
Atlanta, Georgia • Durham, North Carolina • Portland, Oregon + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2017 · Synced May 22, 2026, 12:13 AM EDT
Terminated Phase 2 Interventional
View directory record Official record
Conditions
Acquired Bleeding Disorder, Cardiac Surgery Requiring Cardiopulmonary Bypass
Interventions
activated recombinant human factor VII
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
18
States / cities
Birmingham, Alabama • Tucson, Arizona • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced May 22, 2026, 12:13 AM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Acquired Bleeding Disorder, Bleeding During/Following Surgery
Interventions
standard therapy, activated recombinant human factor VII, placebo
Procedure · Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
12 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 10, 2017 · Synced May 22, 2026, 12:13 AM EDT
Completed Not applicable Interventional
View directory record Official record
Conditions
Osteoarthritis, Hip, Joint Deformities, Acquired, Hip Dislocation, Congenital, Osteonecrosis, Arthritis, Rheumatoid
Interventions
Aquamantys, standard electrocautery (Bovie)
Device
Lead sponsor
Joint Implant Surgeons, Inc.
Other
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
New Albany, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 23, 2012 · Synced May 22, 2026, 12:13 AM EDT
Not listed Not applicable Interventional
View directory record Official record
Conditions
Alagille Syndrome, Pulmonary Artery Stenoses, Acquired Von Willebrand Disease
Interventions
Assessment for bleeding disorder with tailored post-operative care
Other
Lead sponsor
Stanford University
Other
Eligibility
Up to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 5, 2023 · Synced May 22, 2026, 12:13 AM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Abnormalities, Blood Coagulation Disorder, Brain Disease, Cerebrovascular Accident, Vascular Disease
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Up to 45 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced May 22, 2026, 12:13 AM EDT
Withdrawn Phase 3 Interventional
View directory record Official record
Conditions
Acquired Bleeding Disorder, Trauma
Interventions
activated recombinant human factor VII
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
42
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 37 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2012 · Synced May 22, 2026, 12:13 AM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Acquired Antithrombin Deficiency
Interventions
Human plasma derived antithrombin, Placebo
Drug
Lead sponsor
Octapharma
Industry
Eligibility
18 Years to 85 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
9
States / cities
Stanford, California • Miami, Florida • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced May 22, 2026, 12:13 AM EDT
Terminated Phase 2 Interventional
View directory record Official record
Conditions
Coagulopathy
Interventions
Resusix, FP24 (Frozen Plasma)
Biological
Lead sponsor
Entegrion, Inc.
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
3
States / cities
Tucson, Arizona • St Louis, Missouri • Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 6, 2021 · Synced May 22, 2026, 12:13 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Acquired Thrombotic Thrombocytopenic Purpura
Interventions
Caplacizumab, Placebo
Biological
Lead sponsor
Ablynx, a Sanofi company
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
13
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Atlanta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2023 · Synced May 22, 2026, 12:13 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Thrombotic Thrombocytopenic Purpura
Interventions
rituximab
Biological
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
4
States / cities
Atlanta, Georgia • Boston, Massachusetts • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2021 · Synced May 22, 2026, 12:13 AM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Liver Decompensation, Hepatocellular Carcinoma, Non-Hodgkin Lymphoma
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
13 Years and older
Enrollment
2,565 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2013
U.S. locations
39
States / cities
Tucson, Arizona • Davis, California • Orange, California + 31 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced May 22, 2026, 12:13 AM EDT
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Bone Marrow Failure Syndrome, Thalassemia, Sickle Cell Disease, Diamond Blackfan Anemia, Acquired Neutropenia in Newborn, Acquired Anemia Hemolytic, Acquired Thrombocytopenia, Hemophagocytic Lymphohistiocytoses, Wiskott-Aldrich Syndrome, Chronic Granulomatous Disease, Common Variable Immunodeficiency, X-linked Lymphoproliferative Disease, Severe Combined Immunodeficiency, Hurler Syndrome, Mannosidosis, Adrenoleukodystrophy
Interventions
Thiotepa--single daily dose, Thiotepa--escalated dose
Drug
Lead sponsor
University of Florida
Other
Eligibility
3 Months to 39 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 14, 2023 · Synced May 22, 2026, 12:13 AM EDT
Completed Phase 3 Interventional
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
538 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1990
U.S. locations
23
States / cities
Los Angeles, California • San Diego, California • Stanford, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced May 22, 2026, 12:13 AM EDT
Completed Phase 2Phase 3 Interventional Results available
View directory record Official record
Conditions
Acquired Hemophilia A
Interventions
OBI-1
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
8
States / cities
Indianapolis, Indiana • New Orleans, Louisiana • Bethesda, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated May 12, 2021 · Synced May 22, 2026, 12:13 AM EDT
Recruiting Not applicable Interventional
View directory record Official record
Conditions
Aphasia, Acquired, Aphasia, Aphasia, Fluent, Aphasia, Non-fluent, Aphasia Following Cerebral Infarction, Aphasia Following Nontraumatic Intracerebral Hemorrhage
Interventions
High-intensity physical exercise, Low-intensity physical exercise
Behavioral
Lead sponsor
University of California, Berkeley
Other
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
4
States / cities
Berkeley, California • Hayward, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced May 22, 2026, 12:13 AM EDT
Completed Phase 3 Interventional
View directory record Official record
Conditions
Acquired Bleeding Disorder, Intracerebral Haemorrhage
Interventions
eptacog alfa (activated)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
829 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
77
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced May 22, 2026, 12:13 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Acquired Thrombotic Thrombocytopenic Purpura
Interventions
Caplacizumab, Standard of Care
Biological · Other
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
8
States / cities
St Louis, Missouri • Valhalla, New York • Durham, North Carolina + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2022 · Synced May 22, 2026, 12:13 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available
View directory record Official record
Conditions
Foot and Ankle Surgeries, Bunion
Interventions
Tranexamic Acid, Normal saline
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 28, 2020 · Synced May 22, 2026, 12:13 AM EDT
Completed No phase listed Observational Accepts healthy volunteers
View directory record Official record
Conditions
All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis, Asthma, Atopic Dermatitis Eczema, Beta Thalassemia, Bipolar Disorder, Breast Cancer, Celiac Disease, Cervical Cancer, Chronic Inflammatory Demyelinating Polyneuropathy, Chronic Kidney Diseases, Chronic Obstructive Pulmonary Disease, Colon Cancer, Colorectal Cancer, Crohn's Disease, Cystic Fibrosis, Depression, Diabetes Mellitus, Duchenne Muscular Dystrophy, Endometriosis, Epilepsy, Facioscapulohumeral Muscular Dystrophy, G6PD Deficiency, General Anxiety Disorder, Hepatitis B, Hereditary Hemorrhagic Telangiectasia, HIV/AIDS, Human Papilloma Virus, Huntington's Disease, Idiopathic Thrombocytopenic Purpura, Insomnia, Kidney Cancer, Leukemia, Lung Cancer, Lupus Nephritis, Lymphoma, Melanoma, Multiple Myeloma, Multiple Sclerosis, Myositis, Myotonic Dystrophy, Ovarian Cancer, Pancreatic Cancer, Parkinson's Disease, Polycystic Kidney Diseases, Prostate Cancer, Psoriasis, Psoriatic Arthritis, Rosacea, Scleroderma, Sickle Cell Anemia, Sickle Cell Trait, Sjogren's Syndrome, Skin Cancer, Spinal Muscular Atrophy, Systemic Lupus Erythematosus, Thrombotic Thrombocytopenic Purpura, Trisomy 21, Ulcerative Colitis
Interventions
Not listed
Lead sponsor
Sanguine Biosciences
Industry
Eligibility
18 Years to 100 Years
Enrollment
17,667 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced May 22, 2026, 12:13 AM EDT
Terminated Phase 2 Interventional
View directory record Official record
Conditions
Acquired Bleeding Disorder, Bleeding During/Following Surgery
Interventions
standard therapy, placebo, activated recombinant human factor VII
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
12 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
7
States / cities
Little Rock, Arkansas • Duarte, California • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2017 · Synced May 22, 2026, 12:13 AM EDT